<DOC>
	<DOCNO>NCT02693119</DOCNO>
	<brief_summary>This Phase 2 , prospective , randomize , double-masked , vehicle control , single-center study approximately 12 subject LHON evaluate safety , tolerability efficacy elamipretide ( MTP-131 ) topical ophthalmic solution patient population .</brief_summary>
	<brief_title>A Study Investigating Safety , Tolerability , Efficacy Elamipretide ( MTP-131 ) Topical Ophthalmic Solution Treatment Leber 's Hereditary Optic Neuropathy</brief_title>
	<detailed_description />
	<mesh_term>Optic Nerve Diseases</mesh_term>
	<mesh_term>Optic Atrophy , Hereditary , Leber</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<criteria>Adults ≥18 ≤ 50 year old time loss vision second eye . Able provide inform consent willing comply study visit examination Diagnosis LHON base clinical ophthalmic functional/anatomic test finding , satisfactory documentation mitochondrial DNA mutation m.11778G &gt; A Loss vision eye ≥1 year ≤10 year time Screening Visit current clinically stable visual function ( assessed Investigator ) Able selfadminister eye drop demonstrate screen care provider Documentation satisfactorily complete least two previous Humphrey automate visual field test prior screen . Women childbearing potential must agree use birth control specify protocol date sign inform consent form Any ocular pathology require treatment prescription topical ophthalmic drop ( e.g. , glaucoma , dry eye ) Cup disc ratio &gt; 0.8 either eye Media opacity , suboptimal pupillary dilatation , refractive error interfere adequate retinal imaging Known immunocompromised receive systemic immunosuppression Any disease medical condition opinion Investigator would prevent subject participate study might confound study result Participation investigational drug device clinical trial within 30 day prior enrollment , plan participate investigational drug device clinical trial within 30 day study completion Women pregnant lactate Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>LHON</keyword>
	<keyword>Ocuvia™</keyword>
	<keyword>elamipretide</keyword>
	<keyword>MTP-131</keyword>
</DOC>